Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $2.94 Billion |
|---|---|
| Enterprise Value | $3.27 Billion |
| Earnings per Share | $-0.02 |
| Beta | 0.6 |
| Outstanding Shares | 339,220,212 |
| P/E Ratio | 96.23 |
|---|---|
| PEG | -5.77 |
| Price to Sales | 1.24 |
| Price to Book Ratio | 8.66 |
| Enterprise Value to Revenue | 1.31 |
| Enterprise Value to EBIT | 48.41 |
| Enterprise Value to Net Income | 51 |
| Total Debt to Enterprise | 0.18 |
| Debt to Equity | 1.19 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medi...